BioVie Secures FDA Approval for Phase 2 Trial
BioVie Inc. (NASDAQ: BIVI) is pleased to announce that it has received authorization from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 2 trial. This trial will evaluate the effectiveness of bezisterim, a promising treatment aimed at alleviating neurological symptoms related to long COVID.
Milestone Achieved Ahead of Timeline
Reaching this important milestone opens the door to an additional $12.6 million in grant funding from the U.S. Department of Defense (DOD). This financial support will be instrumental for the upcoming trial, marking a significant advancement in our understanding and management of long COVID.
Increasing Awareness of Long COVID
Recent surveys reveal that approximately 5.5% of adults in the U.S. are dealing with long COVID, with around 3.6 million individuals reporting major lifestyle changes due to persistent symptoms. Long COVID encompasses a range of symptoms that continue long after the initial COVID-19 infection has subsided.
Bezisterim: An Innovative Treatment Strategy
Bezisterim is being investigated for its anti-inflammatory effects, which may help alleviate the neurocognitive challenges often experienced by long COVID patients. The upcoming study plans to enroll about 200 participants, focusing on the safety and tolerability of bezisterim over a three-month treatment period, while also assessing its potential to lessen cognitive dysfunction and fatigue.
Understanding Long COVID
Long COVID describes a range of lingering symptoms, including cognitive dysfunction, fatigue, and severe neurological effects, that can persist for months. Chronic inflammation is believed to play a crucial role in these ongoing issues, with researchers indicating that inflammation may contribute to lasting symptoms such as “brain fog.”
Details on the Department of Defense Grant
The DOD has allocated initial funding of $499,200 for preliminary planning, with a commitment to provide an additional $12.6 million upon achieving further milestones. This grant will support essential steps necessary for the forthcoming clinical trial.
Broader Implications of Bezisterim
Bezisterim, also referred to as NE3107, is not only being developed for long COVID but is also under investigation for other serious conditions, including Alzheimer’s and Parkinson’s diseases. Previous research has shown promising results, indicating that it may effectively enhance cognition and alleviate neurological symptoms in patients suffering from these disorders.
BioVie’s Commitment to Advancing Treatment
BioVie Inc. is dedicated to pioneering innovative therapies for complex neurological and liver diseases. With a focus on reducing neuroinflammation, their treatments represent a new frontier for patients facing significant health challenges.
Frequently Asked Questions
What is the purpose of the Phase 2 trial for bezisterim?
The trial aims to assess the safety and effectiveness of bezisterim in alleviating neurocognitive symptoms in patients with long COVID.
How does bezisterim work?
Bezisterim acts as an anti-inflammatory agent that may help regulate inflammation associated with long COVID symptoms.
What are the expected outcomes of the trial?
The trial is designed to evaluate the tolerability, safety, and potential benefits of bezisterim over a three-month period.
Who is eligible to participate in the trial?
Approximately 200 adults experiencing long COVID symptoms will be recruited for this multicenter trial.
What is BioVie’s broader mission?
BioVie is committed to developing innovative therapies that target neurological disorders and liver diseases, ultimately improving the quality of life for patients.
